Middle East & Africa Epilepsy Drugs Market Forecast to 2030 - Regional Analysis

Description

List of Tables

The Middle East & Africa epilepsy drugs market was valued at US$ 593.94 million in 2022 and is expected to reach US$ 741.26 million by 2030; it is estimated to grow at a CAGR of 2.8% from 2022 to 2030.

Increasing Product Approvals Fuels Middle East & Africa Epilepsy Drugs Market

In recent years, there has been a notable increase in the approval of drugs to treat epilepsy, marking a significant step forward in addressing the challenges posed by severe seizures. Growing awareness of the need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs.

Drug approvals and the diversity of new molecular entities (NMEs) upon which new drugs are based have been consistently growing over time. A notable growth in the number of drug approvals annually was also observed in the recent past. Thus, the acceptance of new drugs is rising and resulting in increasing approvals for the products.

Thus, the increasing number of regulatory approvals is becoming a trend in the epilepsy drug market worldwide.

Middle East & Africa Epilepsy Drugs Market Overview

The Middle East & Africa epilepsy drugs market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Epilepsy has several possible causes. The cause of epilepsy can only be identified in 32% of cases, while in the remaining cases, the cause of epilepsy is unidentifiable, i.e., idiomatic epilepsy. Common causes of epilepsy among South Africans include infectious disease, head trauma and alcohol abuse. South Africans have a relatively high mortality rate and high prevalence of epilepsy. According to the latest WHO data published in 2020, deaths due to epilepsy in South Africa reached 1,870, i.e., 0.41% of total deaths. Therefore, the increasing prevalence of epilepsy will upsurge the Middle East & Africa epilepsy drugs market.

Middle East & Africa Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Epilepsy Drugs Market Segmentation

The Middle East & Africa epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Middle East & Africa epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Middle East & Africa epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Middle East & Africa epilepsy drugs market is segmented Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Middle East & Africa epilepsy drugs market.

Product Code: BMIRE00029806

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Epilepsy Drugs Landscape

4.1 Overview

5. Middle East & Africa Epilepsy Drugs Market - Key Industry Dynamics

5.1 Market Drivers
- 5.1.1 Growing Prevalence of Epilepsy
- 5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
- 5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
- 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
- 5.4.1 Increasing Product Approvals
5.5 Impact Analysis

6. Epilepsy Drugs Market - Middle East & Africa Market Analysis

6.1 Middle East & Africa Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030

7. Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

7.1 Overview
7.2 Middle East & Africa Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
- 7.3.1 Overview
- 7.3.2 First Generation Antiepileptics: Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
- 7.4.1 Overview
- 7.4.2 Second Generation Anti-epileptics: Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
- 7.5.1 Overview
- 7.5.2 Third Generation Anti-epileptics: Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Middle East & Africa Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacy: Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
- 8.4.1 Overview
- 8.4.2 Retail Pharmacy Stores: Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis

9.1 Middle East & Africa Epilepsy Drugs Market, by Key Country- Revenue (2022) (US$ Million)

10. Epilepsy Drugs Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Pfizer Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Abbott Laboratories
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sanofi SA
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Teva Pharmaceutical Industries Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Alkem Laboratories Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms